MARKET

ACRV

ACRV

Acrivon Therapeutics, Inc.
NASDAQ
1.560
-0.060
-3.70%
After Hours: 1.580 +0.02 +1.25% 19:10 02/10 EST
OPEN
1.620
PREV CLOSE
1.620
HIGH
1.640
LOW
1.550
VOLUME
974.62K
TURNOVER
--
52 WEEK HIGH
6.12
52 WEEK LOW
1.050
MARKET CAP
49.23M
P/E (TTM)
-0.7328
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ACRV last week (0202-0206)?
Weekly Report · 1d ago
Weekly Report: what happened at ACRV last week (0126-0130)?
Weekly Report · 02/02 10:14
Weekly Report: what happened at ACRV last week (0119-0123)?
Weekly Report · 01/26 10:14
ACRIVON THERAPEUTICS ANNOUNCES LATE-BREAKING ORAL PRESENTATION AT UPCOMING EUROPEAN SOCIETY OF GYNECOLOGICAL ONCOLOGY (ESGO) ANNUAL INTERNATIONAL CONGRESS
Reuters · 01/23 13:11
Analysts Offer Insights on Healthcare Companies: Acrivon Therapeutics, Inc. (ACRV), Ultragenyx Pharmaceutical (RARE) and Teva Pharmaceutical (TEVA)
TipRanks · 01/23 13:10
3 ‘Strong Buy’ Stocks to Buy Now, 1/22/2026, According to Top Analysts
TipRanks · 01/22 13:02
Analysts Offer Insights on Healthcare Companies: Acrivon Therapeutics, Inc. (ACRV), RegenXBio (RGNX) and Nurix Therapeutics (NRIX)
TipRanks · 01/21 16:00
Weekly Report: what happened at ACRV last week (0112-0116)?
Weekly Report · 01/19 10:20
More
About ACRV
Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision oncology medicines. It uses its precision Generative Phosphoproteomics platform, Acrivon Predictive Precision Proteomics (AP3), to develop its pipeline of oncology drug candidates. Its lead candidate, ACR-368, is a selective small molecule inhibitor which targets CHK1 and CHK2 at sub single-digit nM and single-digit nM potency in intact cells, respectively, in a registrational Phase II trial across multiple solid tumor types. Using its AP3 platform, it has developed a predictive OncoSignature test for ACR-368, called ACR-368 OncoSignature, that can predict patient response to ACR-368 monotherapy and therefore improve the clinical overall response rate (ORR) and has the potential to enable drug development. Its preclinical program, ACR-2316, is advancing in investigational new drug-enabling studies. It is a novel, dual WEE1 and PKMYT1 inhibitor small molecule development candidate.

Webull offers Acrivon Therapeutics Inc stock information, including NASDAQ: ACRV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACRV stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ACRV stock methods without spending real money on the virtual paper trading platform.